kreiley

The transparency landscape for the life science industry is continuously evolving, with requirements that seem to be increasing by the minute. At Informa’s recent Transparency, Aggregate Spend & HCP Engagement conference, industry professionals discussed the latest regulations impacting both pharmaceutical and medical device companies. Two areas stood out during these discussions: Illinois and Brazil.

Illinois

House Bill 5517 […]

At Informa’s recent Transparency, Aggregate Spend & HCP Engagement conference, compliance professionals focused heavily on the CMS audits that began in early 2023. Since data collection began in 2013, the CMS’s decision to perform random audits marks a pivotal shift, signaling a new phase in Sunshine Act reporting. Throughout the conference, valuable insights were […]

At Informa’s recent Transparency, Aggregate Spend & HCP Engagement conference, compliance professionals focused heavily on the CMS audits that began in early 2023. Since data collection began in 2013, the CMS’s decision to perform random audits marks a pivotal shift, signaling a new phase in Sunshine Act reporting. Throughout the conference, valuable insights were […]

On Friday, June 28, 2024, the Centers for Medicare and Medicaid Services (CMS) published the 2023 Open Payments data, along with newly submitted and updated payment records for program years 2017-2022. The 2023 data includes transactions from January 1st to December 31st. Applicable manufacturers reported $12.75 billion in reportable payments, ownership and investment interests to […]

MediSpend experts recently presented a webinar focused on the ever-evolving life science transparency regulations around the world. They discussed the newly released Connecticut pharmaceutical sales representative disclosure report, along with recent transparency updates in Denmark and India. The presentation concluded with the status of requirements in Italy and the United Kingdom.

Connecticut

Public Act 23-171 was signed […]

The global compliance landscape is challenging and constantly evolving. Business complexity is increasing, and enforcement risks are intensifying. As a result, we must continuously assess whether we have the tools necessary to proactively identify and manage risks, and ensure these tools engage the entire organization in the compliance process. Understanding our compliance data is becoming […]

Life science organizations are dedicated to developing and manufacturing transformative products that enhance lives. To accomplish this mission, they routinely contract with healthcare professionals (HCPs) to research, develop, market and train on these products. HCPs contribute invaluable insights, expertise and medical credibility by providing both a theoretical and practical approach to the products and treatments.

However, […]

Life sciences professionals engaged in transparency reporting understand the myriad of challenges in compiling necessary data for reporting. Navigating challenges such as incomplete records, discrepancies among data sources, duplicate, or late data submissions can significantly compromise the accuracy of reporting. Compliance and transparency teams often endure heightened stress and sleepless nights over these common issues, […]

MediSpend’s legal experts recently presented a webinar shedding light on the recent transparency updates within the life science industry. The presentation covered key topics, such as updates to CMS’ Open Payments reporting, various state considerations and the newly issued OIG General Compliance Program Guidance. Notably, the webinar highlighted recent developments in compliance regulations in both Italy and […]